Catalog No.
DHE40101
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG2
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
GLP-1 receptor, Glucagon-like peptide 1 receptor, GLP1R, GLP-1-R, GLP-1R
Concentration
3.45 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P43220
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
GMA105
Clone ID
GMA105
Note
For research use only. Not suitable for clinical or therapeutic use.
Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies., PMID:40367985
Gut microbiota regulation by Lactiplantibacillus plantarum SG5 enhances mitochondrial function in Parkinson's disease mice via the GLP-1/PGC-1α pathway., PMID:40368220
Exploring glucagon-like peptide-1 receptor agonists as potential disease-modifying agent in psychiatric and neurodevelopmental conditions: evidence from a drug target Mendelian randomization., PMID:40369498
The Effects of GLP-1 Agonists on Musculoskeletal Health and Orthopedic Care., PMID:40372699
A GLP1R gene variant and sex influence the response to semaglutide treatment in patients with severe obesity., PMID:40384505
Ex vivo lung perfusion with GLP-1R agonist mitigates ischemia/reperfusion injury through pyroptosis modulation in lung transplantation- an experimental study., PMID:40387728
Molecular mechanisms and neural mediators of leptin action., PMID:40393800
Activation of AMPK by GLP-1R agonists mitigates Alzheimer-related phenotypes in transgenic mice., PMID:40394225
GLP-1R agonists protect against Alzheimer's disease by rewiring energy regulation., PMID:40394226
GLP-1R/GCGR dual agonism dissipates hepatic steatosis to restore insulin sensitivity and rescue pancreatic β-cell function in obese male mice., PMID:40399267
Hypertension after solid-organ transplantation: special considerations for management., PMID:40401425
Refining the link between obesity and heart failure: insights from GLP-1 receptor agonist trials and studies adopting direct adiposity measures., PMID:40405237
Case Report: A case of occult insulinoma localized by [18F] FB (ePEG12)12-exendin-4 positron emission tomography with negative findings of selective arterial calcium stimulation test., PMID:40405975
Semaglutide effects on energy balance are mediated by Adcyap1+ neurons in the dorsal vagal complex., PMID:40409256
Outcomes of 68Ga-NODAGA-Exendin-4 PET/CT Guided Surgical Management of Insulinomas in MEN1: A Preliminary Study., PMID:40409292
Geniposide ameliorates cholesterol accumulation and promotes osteoblast differentiation by mediating the GLP-1R/AMPK/SREBP2 pathway., PMID:40414881
APM-Related gene signature model to predict prognosis and immunotherapy response in hepatocellular carcinoma., PMID:40423787
Semaglultide targets Spp1+ microglia/macrophage to attenuate neuroinflammation following perioperative stroke., PMID:40426210
Decoding the impact of glucose-dependent insulinotropic polypeptide receptor (GIPR) agonist on cardiometabolic health: inflammatory mediators at the focus., PMID:40426228
GLP-1R Agonists and Their Therapeutic Potential in Inflammatory Bowel Disease and Other Immune-Mediated Inflammatory Diseases, a Systematic Review of the Literature., PMID:40426955
Antidiabetic GLP-1 Receptor Agonists Have Neuroprotective Properties in Experimental Animal Models of Alzheimer's Disease., PMID:40430434
Association of glucagon-like peptide-1 receptor agonists with atrial fibrillation, cardiac arrest, and ventricular fibrillation: Casual evidence from a drug target Mendelian randomization., PMID:40442813
GLP-1R Polymorphisms Modify the Relationship Between Exposure to Gestational Diabetes and Offspring BMI Growth: The EPOCH Study., PMID:40443355
Association of glucagon-like peptide-1 receptor agonists and seven common mental disorders: A drug target and mediation Mendelian randomization., PMID:40447157
Advances in Endocrine Tumor PET Imaging Targeting CXCR4 and GLP-1., PMID:40447542
Novel Insights into the Causal Relationship between Antidiabetic Drugs and Adverse Perinatal Outcomes: A Mendelian Randomization Study., PMID:40452211
A GLP-1R/Y1 receptor/Y2 receptor triple agonist decreases fentanyl-evoked dopamine release in the nucleus accumbens and attenuates fentanyl taking and seeking in rats., PMID:40456683
An immune-related signature based on molecular subtypes for predicting the prognosis and immunotherapy efficacy of hepatocellular carcinoma., PMID:40458412
Biased agonism of GLP-1R and GIPR enhances glucose lowering and weight loss, with dual GLP-1R/GIPR biased agonism yielding greater efficacy., PMID:40460831
Molecular Design of Unimolecular Tetra-Receptor Agonists., PMID:40461942
Contractile effects of retatrutide in isolated mouse atrial preparations., PMID:40464942
State-dependent central synaptic regulation by GLP-1 is essential for energy homeostasis., PMID:40467923
The therapeutic potential of glucagon-like peptide-1 receptor analogs for neuroinflammation in the setting of asthma., PMID:40474934
Activation of GLP-1 receptors enhances the osteogenic differentiation process of STRO-1-positive BMSCs., PMID:40478323
Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis., PMID:40479843
Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes., PMID:40481478
Mechanism-guided drug development and treatment for liver fibrosis: a clinical perspective., PMID:40492139
GLP-1RA and the possible skin aging., PMID:40498168
The central signaling pathways related to metabolism-regulating hormones of the gut-brain axis: a review., PMID:40500780
De novo design of miniprotein agonists and antagonists targeting G protein-coupled receptors., PMID:40501737
Differential Role of Phosphorylation in Glucagon Family Receptor Signaling Revealed by Mass Spectrometry., PMID:40503712
The Premise of the Paradox: Examining the Evidence That Motivated GIPR Agonist and Antagonist Drug Development Programs., PMID:40507574
RNA-Seq and WGCNA Identify Key Regulatory Modules and Genes Associated with Water-Holding Capacity and Tenderness in Sheep., PMID:40509035
Designing structure-specific and switchable allosteric effectors for GPCRs based on the causality and energetics of inherent signaling., PMID:40513649
Tirzepatide, a dual GIP/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: comparison to liraglutide., PMID:40517248
GLP-1R in diabetes mellitus: from basic discovery to therapeutics development., PMID:40520185
Therapeutic Targeting of the GIP Receptor-Revisiting the Controversies., PMID:40521880
Effectiveness and tolerability of liraglutide as add-on treatment in patients with obesity and high-frequency or chronic migraine: A prospective pilot study., PMID:40525593
Hypophagia and body weight loss by tirzepatide are accompanied by fewer GI adverse events compared to semaglutide in preclinical models., PMID:40532005
For research use only. Not for human or drug use.
